MedPath

Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives

Completed
Conditions
Hypertension
Obesity
Registration Number
NCT00539487
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This observational non-interventional study will assess (under conditions of clinical practice in daily routine) the antihypertensive efficacy of telmisartan treatment with or without active promotion of lifestyle changes in hypertensive patients at high cardiovascular risk

Detailed Description

Study Design:

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
5827
Inclusion Criteria

patients with essential hypertension aged >/= 18 years with one of the following risk factors: history of coronary artery disease or stroke/TIA or peripheral artery disease or diabetes mellitus.

Exclusion Criteria

according to SPC

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Blood pressure reduction4 month
Secondary Outcome Measures
NameTimeMethod
Change in metabolic parameters Safety

Trial Locations

Locations (94)

Boehringer Ingelheim Investigational Site 1

🇩🇪

Übach-Palenberg, Germany

Boehringer Ingelheim Investigational Site 2

🇩🇪

Übach-Palenberg, Germany

Boehringer Ingelheim Investigational Site 3

🇩🇪

Zwickau, Germany

Boehringer Ingelheim Investigational Site 4

🇩🇪

Zwickau, Germany

Boehringer Ingelheim Investigational Site 5

🇩🇪

Zwickau, Germany

Boehringer Ingelheim Investigational Site 6

🇩🇪

Zwickau, Germany

Boehringer Ingelheim Investigational Site 7

🇩🇪

Zwickau, Germany

Boehringer Ingelheim Investigational Site 8

🇩🇪

Wolfsburg, Germany

Boehringer Ingelheim Investigational Site

🇩🇪

Ühlingen-Birkendorf, Germany

Boehringer Ingelheim Investigational Site 10

🇩🇪

Wiesbaden, Germany

Scroll for more (84 remaining)
Boehringer Ingelheim Investigational Site 1
🇩🇪Übach-Palenberg, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.